Indeed, a high sensitivity to PARP inhibitors, alone or in combination with cisplatin, have been reported in a panel of TGCTs cell lines, letting envisage an additional therapeutic approach to utilize in tumours testis [14]. The gene discussed is PARP1; the disease is neoplasm.